Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 6 records in total 6
    records per page

    The association of ABO blood group HGNC with the asymptomatic COVID-19 MESHD cases in India

    Authors: Prajjval Pratap Singh; Abhishek K Srivastava; Sudhir K Upadhyay; Ashish Singh; Pranav Gupta; Sanjeev Maurya; Shashank Upadhyay; Rudra K Pandey; Anshika Shrivastava; Priya Dev; Vanya Singh; Rahul Mishra; Manoj K Shukla; Govind Chaubey; Pradeep Kumar; Vandana Rai; Yamini B Tripathy; Abhishek Pathak; Vijaya N Mishra; Chandana Basu Mallick; Panjak Shrivastava; Gyaneshwer Chaubey

    doi:10.1101/2021.04.01.21254681 Date: 2021-04-06 Source: medRxiv

    The COVID-19 pandemic MESHD has resulted several waves of infection in many countries worldwide. The large variations in case fatality ratio among different geographical regions suggests that the human susceptibility against this virus varies substantially. Several studies from different parts of the world showed a significant association of ABO blood group HGNC and COVID-19 MESHD susceptibility. It was shown that individuals with blood group O are at the lower risk of coronavirus infection MESHD. To establish the association of ABO blood group HGNC in SARS-CoV-2 susceptibility, we for the first time analysed SARS-CoV-2 neutralising antibodies as well as blood groups among 509 random individuals from three major districts of Eastern Uttar Pradesh region of India. . Interestingly, we found neutralising antibodies in significantly higher percentage of people with blood group AB (0.36) followed by B (0.31), A (0.22) and lowest in people with blood group O (0.11). This indicates that people with blood group AB are at comparatively higher risk of infection than other blood groups. Further, in line to previous reports we too observed that people with blood group O have significantly decreased risk of SARS-CoV-2 infection MESHD. Thus, among the asymptomatic SARS-CoV-2 infected MESHD individuals with blood group AB has highest, whilst blood group O has lowest risk of infection.

    Severity of Respiratory Infections due to SARS-CoV-2 in Working Population: Age and Body Mass Index Outweigh ABO HGNC Blood Group

    Authors: Johannes Schetelig; Henning Baldauf; Sarah Wendler; Falk Heidenreich; Ruben Real; Martin Kolditz; Andrea Rosner; Alexander Dalpke; Katja de With; Vinzenz Lange; Jan Markert; Ralf Barth; Carolin Bunzel; Dennis Endert; Jan Hofmann; Juergen Sauter; Stefanie N Bernas; Alexander H Schmidt

    doi:10.1101/2020.11.05.20226100 Date: 2020-11-06 Source: medRxiv

    Background. With increasing rates of SARS-CoV-2 infections MESHD and the intention to avoid a lock-down, the risks for the working population are of great interest. No large studies have been conducted which allow risk assessment for this population. Methods. DKMS is a non-profit donor center for stem cell donation and reaches out to registered volunteers between 18 and 61 years of age. To identify risk factors for severe COVID-19 MESHD courses in this population we performed a cross-sectional study. Self-reported data on oro- or nasopharyngeal swabs, risk factors, symptoms and treatment were collected with a health questionnaire and linked to existing genetic data. We fitted multivariable logistic regression models for the risk of contracting SARS-CoV-2, risk of severe respiratory infection MESHD and risk of hospitalization. Findings. Of 4,440,895 contacted volunteers 924,660 (20.8%) participated in the study. Among 157,544 participants tested, 7,948 reported SARS-CoV-2 detection. Of those, 947 participants (11.9%) reported an asymptomatic course, 5,014 (63.1%) mild/moderate respiratory infections MESHD, and 1,987 (25%) severe respiratory tract infections MESHD. In total, 286 participants (3.6%) were hospitalized for respiratory tract infections MESHD. The risk of hospitalization in comparison to a 20-year old person of normal weight was 2.1-fold higher (95%-CI, 1.2-3.69, p=0.01) for a person of same age with a BMI between 35-40 kg/m2, it was 5.33-fold higher (95%-CI, 2.92-9.70, p<0.001) for a 55-year old person with normal weight and 11.2-fold higher (95%-CI, 10.1-14.6, p<0.001) for a 55-year old person with a BMI between 35-40 kg/m2. Blood group A was associated with a 1.15-fold higher risk for contracting SARS-CoV-2 (95%-CI 1.08-1.22, p<0.001) than blood group O but did not impact COVID-19 MESHD severity. Interpretation. In this relatively healthy population, the risk for hospitalizations due to SARS-CoV-2 infections MESHD was moderate. Age and BMI were major risk factors. These data may help to tailor risk-stratified preventive measures.

    The Lebanese Cohort for COVID-19 MESHD; A Challenge for the ABO Blood Group HGNC System

    Authors: Athar Khalil; Mahmoud Hassoun; Rita Feghali

    doi:10.1101/2020.08.02.20166785 Date: 2020-08-04 Source: medRxiv

    A sudden outbreak of pneumonia MESHD caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has rapidly spread all over the world facilitating the declaration of the resultant disease as a pandemic in March,2020. In Lebanon, the fast action of announcing a state of emergency with strict measures was among the factors that helped in achieving a successful containment of the disease in the country. Predisposing factors for acquiring COVID-19 MESHD and for developing a severe form of this disease were postulated to be related to epidemiological and clinical characteristics as well as the genomics signature of a given population or its environment. Biological markers such as the ABO blood group HGNC system was amongst those factors that were proposed to be linked to the variability in the disease course and/or the prevalence of this infection among different groups. We therefore conducted the first retrospective case-control study in the Middle-East and North Africa that tackles the association between the blood group types and the susceptibility as well as the severity of SARS-CoV2 infection MESHD. Opposing to the current acknowledged hypothesis, our results have challenged the association significance of this system with COVID-19 MESHD. Herein, we highlighted the importance of studying larger cohorts using more rigorous approaches to diminish the potential confounding effect of some underlying comorbidities and genetic variants that are known to be associated with the ABO blood group HGNC system.

    Genetic architecture of host proteins interacting with SARS-CoV-2

    Authors: Maik Pietzner; Eleanor Wheeler; Julia Carrasco-Zanini; Johannes Raffler; Nicola D. Kerrison; Erin Oerton; Victoria P.W. Auyeung; Chris Finan; Juan P. Casas; Rachel Ostroff; Steve A. Williams; Gabi Kastenmüller; Markus Ralser; Eric G. Gamazon; Nicholas J. Wareham; Aroon Dinesh Hingorani; Claudia Langenberg

    doi:10.1101/2020.07.01.182709 Date: 2020-07-01 Source: bioRxiv

    Strategies to develop therapeutics for SARS-CoV-2 infection MESHD may be informed by experimental identification of viral-host protein interactions in cellular assays and measurement of host response proteins in COVID-19 MESHD patients. Identification of genetic variants that influence the level or activity of these proteins in the host could enable rapid in silico assessment in human genetic studies of their causal relevance as molecular targets for new or repurposed drugs to treat COVID-19 MESHD. We integrated large-scale genomic and aptamer-based plasma proteomic data from 10,708 individuals to characterize the genetic architecture of 179 host proteins reported to interact with SARS-CoV-2 proteins MESHD or to participate in the host response to COVID-19 MESHD. We identified 220 host DNA sequence variants acting in cis ( MAF HGNC 0.01-49.9%) and explaining 0.3-70.9% of the variance of 97 of these proteins, including 45 with no previously known protein quantitative trait loci (pQTL) and 38 encoding current drug targets. Systematic characterization of pQTLs across the phenome identified protein-drug-disease links, evidence that putative viral interaction partners such as MARK3 HGNC affect immune response, and establish the first link between a recently reported variant for respiratory failure MESHD of COVID-19 MESHD patients at the ABO HGNC locus and hypercoagulation MESHD, i.e. maladaptive host response. Our results accelerate the evaluation and prioritization of new drug development programmes and repurposing of trials to prevent, treat or reduce adverse outcomes. Rapid sharing and dynamic and detailed interrogation of results is facilitated through an interactive webserver (

    Proteomic Profiling in Biracial Cohorts Implicates DC-SIGN HGNC as a Mediator of Genetic Risk in COVID-19 MESHD

    Authors: Daniel H. Katz; Usman A. Tahir; Debby Ngo; Mark D. Benson; Alexander G. Bick; Akhil Pampana; Yan Gao; Michelle J. Keyes; Adolfo Correa; Sumita Sinha; Dongxiao Shen; Qiong Yang; Jeremy M. Robbins; Zsu-Zsu Chen; Daniel E. Cruz; Bennet Peterson; Pradeep Natarajan; Ramachandran S. Vasan; Gustav Smith; Thomas J. Wang; Robert E. Gerszten

    doi:10.1101/2020.06.09.20125690 Date: 2020-06-11 Source: medRxiv

    COVID-19 MESHD is one of the most consequential pandemics in the last century, yet the biological mechanisms that confer disease risk are incompletely understood. Further, heterogeneity in disease outcomes is influenced by race, though the relative contributions of structural/social and genetic factors remain unclear. Very recent unpublished work has identified two genetic risk loci that confer greater risk for respiratory failure MESHD in COVID-19 MESHD: the ABO HGNC locus and the 3p21.31 locus. To understand how these loci might confer risk and whether this differs by race, we utilized proteomic profiling and genetic information from three cohorts including black and white participants to identify proteins influenced by these loci. We observed that variants in the ABO HGNC locus are associated with levels of CD209 HGNC/ DC-SIGN HGNC, a known binding protein for SARS-CoV MESHD and other viruses, as well as multiple inflammatory and thrombotic proteins, while the 3p21.31 locus is associated with levels of CXCL16 HGNC, a known inflammatory chemokine. Thus, integration of genetic information and proteomic profiling in biracial cohorts highlights putative mechanisms for genetic risk in COVID-19 MESHD disease.

    The ABO blood group HGNC locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis

    Authors: David Ellinghaus; Frauke Degenhardt; Luis Bujanda; Maria Buti; Agustin Albillos; Pietro Invernizzi; Javier Fernandez; Daniele Prati; Guido Baselli; Rosanna Asselta; Marit Maehle Grimsrud; Chiara Milani; Fatima Aziz; Jan Kassens; Sandra May; Mareike Wendorff; Lars Wienbrandt; Florian Uellendahl-Werth; Tenghao Zheng; Xiaoli Yi; Raul de Pablo; Adolfo Garrido Chercoles; Adriana Palom; Alba-Estela Garcia-Fernandez; Francisco Rodriguez-Frias; Alberto Zanella; Alessandra Bandera; Alessandro Protti; Alessio Aghemo; Ana Lleo de Nalda; Andrea Biondi; Andrea Caballero-Garralda; Andrea Gori; Anja Tanck; Anna Latiano; Anna Ludovica Fracanzani; Anna Peschuck; Antonio Julia; Antonio Pesenti; Antonio Voza; David Jimenez; Beatriz Mateos; Beatriz Nafria Jimenez; Carmen Quereda; Claudio Angelini; Cristina Cea; Aurora Solier; David Pestana; Elena Sandoval; Elvezia Maria Paraboschi; Enrique Navas; Ferruccio Ceriotti; Filippo Martinelli-Boneschi; Flora Peyvandi; Francesco Blasi; Luis Tellez; Albert Blanco-Grau; Giacomo Grasselli; Giorgio Costantino; Giulia Cardamone; Giuseppe Foti; Serena Aneli; Hayato Kurihara; Hesham ElAbd; Ilaria My; Javier Martin; Jeanette Erdmann; Jose Ferrusquia-Acosta; Koldo Garcia-Etxebarria; Laura Izquierdo-Sanchez; Laura Rachele Bettini; Leonardo Terranova; Leticia Moreira; Luigi Santoro; Luigia Scudeller; Francisco Mesonero; Luisa Roade; Marco Schaefer; Maria Carrabba; Maria del Mar Riveiro Barciela; Maria Eloina Figuera Basso; Maria Grazia Valsecchi; Maria Hernandez-Tejero; Marialbert Acosta-Herrera; Mariella D'Angio; Marina Baldini; Marina Cazzaniga; Martin Schulzky; Maurizio Cecconi; Michael Wittig; Michele Ciccarelli; Miguel Rodriguez-Gandia; Monica Bocciolone; Monica Miozzo; Nicole Braun; Nilda Martinez; Orazio Palmieri; Paola Faverio; Paoletta Preatoni; Paolo Bonfanti; Paolo Omodei; Paolo Tentorio; Pedro Castro; Pedro M. Rodrigues; Aaron Blandino Ortiz; Ricardo Ferrer Roca; Roberta Gualtierotti; Rosa Nieto; Salvatore Badalamenti; Sara Marsal; Giuseppe Matullo; Serena Pelusi; Valter Monzani; Tanja Wesse; Tomas Pumarola; Valeria Rimoldi; Silvano Bosari; Wolfgang Albrecht; Wolfgang Peter; Manuel Romero Gomez; Mauro D'Amato; Stefano Duga; Jesus M. Banales; Johannes Roksund Hov; Trine Folseraas; Luca Valenti; Andre Franke; Tom Hemming Karlsen

    doi:10.1101/2020.05.31.20114991 Date: 2020-06-02 Source: medRxiv

    Background. Respiratory failure MESHD is a key feature of severe Covid-19 MESHD and a critical driver of mortality, but for reasons poorly defined affects less than 10% of SARS-CoV-2 infected MESHD patients. Methods. We included 1,980 patients with Covid-19 MESHD respiratory failure MESHD at seven centers in the Italian and Spanish epicenters of the SARS-CoV-2 pandemic in Europe (Milan, Monza, Madrid, San Sebastian and Barcelona) for a genome-wide association analysis. After quality control and exclusion of population outliers, 835 patients and 1,255 population-derived controls from Italy, and 775 patients and 950 controls from Spain were included in the final analysis. In total we analyzed 8,582,968 single-nucleotide polymorphisms (SNPs) and conducted a meta-analysis of both case-control panels. Results. We detected cross-replicating associations with rs11385942 at chromosome 3p21.31 and rs657152 at 9q34, which were genome-wide significant (P<5x10-8) in the meta-analysis of both study panels, odds ratio [OR], 1.77; 95% confidence interval [CI], 1.48 to 2.11; P=1.14x10-10 and OR 1.32 HGNC (95% CI, 1.20 to 1.47; P=4.95x10-8), respectively. Among six genes at 3p21.31, SLC6A20 HGNC encodes a known interaction partner with angiotensin converting enzyme 2 HGNC ( ACE2 HGNC). The association signal at 9q34 was located at the ABO blood group HGNC locus and a blood-group-specific analysis showed higher risk for A-positive individuals (OR=1.45, 95% CI, 1.20 to 1.75, P=1.48x10-4) and a protective effect for blood group O (OR=0.65, 95% CI, 0.53 to 0.79, P=1.06x10-5). Conclusions. We herein report the first robust genetic susceptibility loci for the development of respiratory failure MESHD in Covid-19 MESHD. Identified variants may help guide targeted exploration of severe Covid-19 MESHD pathophysiology.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.